Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.
Johnson WT, Epstein-Peterson ZD, Ganesan N, Pak T, Chang T, Dao P, Moskowitz AJ, Stuver RN, Ghione P, Galasso N, Khan N, Palomba ML, Caron PC, Kumar A, Tamari R, Lue JK, Noy A, Falchi L, Intlekofer AM, Gyurkocza B, Perales MA, Scordo M, Herskovits AZ, Salles G, Vardhana SA, Horwitz SM. Johnson WT, et al. Haematologica. 2024 Sep 1;109(9):2998-3003. doi: 10.3324/haematol.2023.284179. Haematologica. 2024. PMID: 38752279 Free PMC article. No abstract available.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Current Treatment of Peripheral T-cell Lymphoma.
Stuver R, Epstein-Peterson ZD, Johnson WT, Khan N, Lewis N, Moskowitz AJ, Sauter CS, Horwitz S. Stuver R, et al. Among authors: johnson wt. Oncology (Williston Park). 2022 May 9;36(5):293-305. doi: 10.46883/2022.25920960. Oncology (Williston Park). 2022. PMID: 35576176
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, Matasar MJ, Noy A, Hamilton AM, Hamlin P, Caron PC, Straus DJ, Intlekofer AM, Lee Batlevi C, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles G, Dogan A, Schultz ND, Arcila ME, Horwitz SM. Johnson WT, et al. Blood Adv. 2023 Sep 12;7(17):5172-5186. doi: 10.1182/bloodadvances.2023009953. Blood Adv. 2023. PMID: 37078708 Free PMC article.
Retrospective characterization of nodal marginal zone lymphoma.
Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Stuver R, et al. Among authors: johnson wt. Blood Adv. 2023 Sep 12;7(17):4838-4847. doi: 10.1182/bloodadvances.2022009587. Blood Adv. 2023. PMID: 37307213 Free PMC article. Review.
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
Lue JK, Luttwak E, Rivas-Delgado A, Irawan H, Boardman A, Caron PC, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Palomba ML, Steiner R, Stuver R, Torka P, Vardhana S, Zelenetz AD, Schoder H, Imber B, Yahalom J, Zhang Y, Galera P, Dogan A, Aypar U, Salles G. Lue JK, et al. Blood Cancer J. 2024 Oct 14;14(1):178. doi: 10.1038/s41408-024-01148-x. Blood Cancer J. 2024. PMID: 39402034 Free PMC article. No abstract available.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278. Online ahead of print. J Clin Oncol. 2024. PMID: 39661923
Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms.
Isabelle C, Johnson WT, McConnell K, Vogel A, Brammer JE, Boles A, Keller R, Sindaco P, Nisenfeld L, Uppal G, Nikbakht N, Calabretta B, Porazzi P, Gong J, Chakravarti N, Porcu P, Mishra A. Isabelle C, et al. Among authors: johnson wt. Blood Adv. 2023 Jul 25;7(14):3637-3641. doi: 10.1182/bloodadvances.2023009807. Blood Adv. 2023. PMID: 36989058 Free PMC article. No abstract available.
179 results